Castration resistance is defined as either clinical progression, such as the development of metastatic disease or progression of pre-existing disease, or biochemical progression, characterized by three consecutive rises in PSA levels above nadir, in the presence of castrate levels of circulating testosterone 40. This evidence concerns the gene KLK3 and metastatic neoplasm.